Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc Acexamate in advanced compensated chronic liver disease
2024-518242-24-00Phase 3Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic liver disease (CLD) comparing Zinc Acexamate (COPINAL) with Placebo (2 arms). Planned start Oct 2024; status: authorised.
02
Drugs
zinc acexamate
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on 2024-518242-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518242-24-00.